Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models

Area of Science:

• Oncology
• Genetics
• Preclinical Research

Background:

• Genetically engineered mouse (GEM) models are crucial for preclinical cancer therapy testing.
• However, challenges such as variable tumor latency, incomplete penetrance, and complex breeding hinder their utility.
• A novel transplantation strategy is needed to improve the reliability of these models.

Purpose of the Study:

• To describe and validate a tumor transplantation strategy for genetically engineered mouse models.
• To overcome limitations of traditional GEM models in preclinical cancer therapy research.
• To establish a reproducible method for generating mammary tumors in mice for drug testing.

Main Methods:

• Tumor fragments or cell suspensions from various GEMs (e.g., MMTV-PyMT, Her2/neu, wnt1) were transplanted into syngeneic or immunosuppressed mice.
• Tumor development, histopathology, gene expression, and metastasis were monitored.
• Serial passages and drug sensitivity assays were performed.

Main Results:

• Transplanted anterior tumors grew faster than posterior tumors, with growth rate correlating to cell number.
• The transplantation method was reproducible across multiple GEMs.
• High metastasis rates were observed in PyMT, BRCA1/p53(+/-), and wnt1/p53(+/-) models (>90%, 40%, 40% respectively).
• Transplanted PyMT tumors showed similar gene expression and drug sensitivity to original tumors.

Conclusions:

• Tumor transplantation in GEMs provides a consistent cohort of mice with synchronized tumor development.
• This method facilitates well-defined metastasis studies within a characterized genetic background.
• The strategy enhances the reliability of preclinical anticancer therapy testing using GEM models.